[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353546-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353546-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ethnic-disparities-in-metabolic-dysfunction-associated-steatotic-liver-disease-and-clinical-outcomes-original-research","Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes - Original Research","","Large multi-ethnic cohort analysis evaluates ethnic differences in metabolic dysfunction-associated steatotic liver disease (MASLD) and downstream clinical outcomes in the U.S. Adults diagnosed with MASLD from 2008–2018 were identified in TriNetX and followed through August 2025. Propensity score matching compared Asians and Native Hawaiian and Pacific Islanders (NHPI) versus White participants while adjusting for key metabolic and cardiovascular covariates. Asians and NHPI showed distinct outcome profiles, supporting the need for ethnicity-tailored MASLD management strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ethnic-disparities-in-metabolic-dysfunction-associated-steatotic-liver-disease-and-clinical-outcomes-original-research/353546/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ethnic-disparities-in-metabolic-dysfunction-associated-steatotic-liver-disease-and-clinical-outcomes-original-research/353546.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study goal regarding MASLD outcomes?","Question",{"text":63,"@type":64},"To assess whether clinical outcomes in the U.S. differ across ethnic groups, with emphasis on Asians and Native Hawaiian and Pacific Islanders (NHPI) compared with White participants.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants and outcomes selected in the study?",{"text":68,"@type":64},"Adults (≥18 years) diagnosed with MASLD between January 2008 and December 2018 were identified in the TriNetX national database and followed through August 2025.",{"name":70,"@type":61,"acceptedAnswer":71},"Which outcomes differed by ethnicity after propensity score matching?",{"text":72,"@type":64},"After matching, Asians and NHPI had different profiles: Asians had lower cirrhosis rates than Whites, while NHPI showed a lower non-HCC cancer rate but a higher CKD risk; all-cause mortality was lower in Asians but not in NHPI.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353546,1790197444,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 09 January 2026 DOI 10.3389/fendo.2025.1739137  \nOPEN ACCESS  \nEDITED BY  \nRashu Barua,  \nNew York University, United States  \nREVIEWED BY  \nMd Hasif Sinha,  \nLouisiana State University Health Shreveport, United States  \nMohammad Abul Hasnat, Shahjalal University of Science and Technology, Bangladesh  \n*CORRESPONDENCE  \nYusuke Miyatani  \n[yusukemi@hawaii.edu](yusukemi@hawaii.edu)  \nRECEIVED 04 November 2025  \nREVISED 28 November 2025  \nACCEPTED 16 December 2025  \nPUBLISHED 09 January 2026  \nCITATION  \nMiyatani Y, Ogawa A, Sempokuya T, Tran C, James D, Seto T, Shikuma C and Kuwada SK (2026) Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes.  \nFront. Endocrinol. 16:1739137 .  \ndoi: 10.3389/fendo.2025.1739137  \nCOPYRIGHT  \n© 2026 Miyatani, Ogawa, Sempokuya, Tran, James, Seto, Shikuma and Kuwada. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nEthnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes  \nYusuke Miyatani 1*, Aoi Ogawa 1, Tomoki Sempokuya 1,2, Chuong Tran 1,2, Davis James 1, Todd Seto 1,2, Cecilia Shikuma 1 and Scott K. Kuwada 1,2,3  \n1 Department of Medicine, John A. Burns School of Medicine, University of Hawai’ i, Honolulu,  \nHI, United States, 2 Department of Medicine, The Queen’s Medical Center, Honolulu, HI, United States, 3 University of Hawaii Cancer Center, Honolulu, HI, United States  \nBackground: While metabolic dysfunction-associated steatotic liver disease (MASLD) has become increasingly prevalent worldwide, multi-ethnic differences within a shared geography and lifestyle, have not been fully examined. What remains poorly characterized are the clinical outcomes for ethnic minorities in the U.S., particularly Asians and Native Hawaiian and Paciﬁc Islanders (NHPI), compared with White people/persons/person.  \nMethods: Adults (aged ≥18 years) diagnosed with MASLD between January 2008 and December 2018 were identiﬁed in the TriNetX national database using the ICD-10 codes and followed outcomes through August 2025 . Propensity score matching was conducted to compare Asians and NHPI with White people/ persons/person with MASLD, adjusting for age, gender, body mass index, hypertension, type 2 diabetes, hyperlipidemia, and smoking status. Hazard ratios (HR) with 95% conﬁdence intervals were estimated for the major outcomes: all-cause mortality, cirrhosis, and hepatocellular carcinoma (HCC) . The effects of extrahepatic diseases related to metabolic diseases, such as myocardial infarction (MI), heart failure (HF), chronic kidney disease (CKD), and non-HCC cancer, were examined in the analyses.  \nResults: A total of 188,328 White, 14,475 Asian, and 2,390 NHPI patients living in the U. S. (United States of America) with MASLD were identiﬁed with a median follow-up of over 8 years. After propensity score matching, Asian and NHPI demonstrated signiﬁcantly lower rates of cirrhosis than White people/persons/ person. In Asians, the risk of HCC increased with longer follow-up period, and with ≥5 years of follow-up, HCC risk signiﬁcantly exceeded that of White people/ persons/person. Asians had lower rates of CKD, MI, HF, and non-HCC cancers than White people/persons/person. NHPI had a signiﬁcantly lower rate of nonHCC cancers but a higher risk of CKD compared with White people/persons/ person. All-cause mortality was lower among Asians, but not in NHPI, compared with White people/persons/person.  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \nConclusions: In a large, multiethnic U","cbCaigT3wcnvWIGm","https://ap.wps.com/l/cbCaigT3wcnvWIGm","pdf",1354477,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What was the study goal regarding MASLD outcomes?\",\"answer\":\"To assess whether clinical outcomes in the U.S. differ across ethnic groups, with emphasis on Asians and Native Hawaiian and Pacific Islanders (NHPI) compared with White participants.\"},{\"question\":\"How were participants and outcomes selected in the study?\",\"answer\":\"Adults (≥18 years) diagnosed with MASLD between January 2008 and December 2018 were identified in the TriNetX national database and followed through August 2025.\"},{\"question\":\"Which outcomes differed by ethnicity after propensity score matching?\",\"answer\":\"After matching, Asians and NHPI had different profiles: Asians had lower cirrhosis rates than Whites, while NHPI showed a lower non-HCC cancer rate but a higher CKD risk; all-cause mortality was lower in Asians but not in NHPI.\"}]","Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes - Original Research | PDF",1790105987,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e76001c134c7b210ed63c000164c72c4.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af8b0b25625b4304c6ddb8d941830ce2.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f2661e661927e301c0b10d1722f3f5d.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc4c0abe46ff0671763e9b39f43fc791.webp",980,1385]